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molecules is also a powerful negative regulator of T-cell
activation and autoreactivity.
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The initiation of immune responses usually requires
interactions of T lymphocytes with antigen-presenting
cells. The specificity of these interactions depends on the
recognition by the T cell’s antigen receptor of an antigenic
peptide presented in a complex with molecules of the
major histocompatibility complex (MHC). But a successful
immune response requires additional costimulation of the
T cell by molecules on the antigen-presenting cell.
Notable amongst such costimulatory molecules are those of
the B7 family, CD80 and CD86. These two molecules each
bind to the T-cell receptors CD28 and CTLA-4 (cytotoxic
T lymphocyte-associated molecule-4) and trigger cytokine
production and activation of the T cell. Although the
overall response to stimulation by the B7 family is strong
activation, it has recently become apparent that triggering
CTLA-4 has inherently different effects on T-cell activa-
tion than does triggering CD28 (reviewed in [1,2]). Here
we discuss recent developments showing that CTLA-4 is
an important negative regulator of T-cell activation.
CTLA-4 genetics and biochemistry
CTLA-4 was first identified in a search for genes
expressed preferentially in cytotoxic T cells: its cDNA
clone was detected in a library of cDNAs from a cytotoxic
T-cell line following subtraction of cDNAs hybridizing to
RNAs from a B-cell lymphoma [3]. Early studies showed
that CTLA-4 shares amino-acid sequence homology with
CD28, another molecule of the immunoglobulin super-
family that has only a single V-type domain. Both CTLA-4
and CD28 are homodimers with a single interchain disul-
fide bond. Moreover, the CTLA-4 and CD28 genes map
in the same chromosomal regions in mouse and man, and
are about 100 kilobases apart in the human genome. These
findings suggest that the two genes are the products of a
pre-speciation duplication event. CTLA-4 and CD28 have
similar lymphocyte-restricted tissue distribution, but
CTLA-4 is expressed only after lymphocyte activation
whereas CD28 is also expressed on resting lymphocytes.
The amino-acid sequence of the cytoplasmic domain of
CTLA-4 is completely conserved between man, mouse,
rat and rabbit, strongly suggesting that the region has an
important function. The cytoplasmic tail of CTLA-4
includes a binding site (-Tyr–Val–Lys–Met-) for the Src
homology 2 (SH2) domains of the p85 subunit of
phosphatidylinositol (PI) 3-kinase, which is commonly an
element of intracellular signal transduction pathways.
There is also a potential site for serine phosphorylation 
(-Arg–Ser–Pro–Leu-), which could be recognized by a
proline-dependent serine/threonine protein kinase. One
function of the cytoplasmic domain of CTLA-4 is to regu-
late its subcellular localization and cell-surface expression.
Unlike CD28, CTLA-4 is primarily retained intracellu-
larly in Golgi or post-Golgi compartment(s) [4]. The
unique subcellular distribution of CTLA-4 is regulated by
the sequence motif -Thr–Thr–Gly–Val–Tyr–Val–Lys–
Met–Pro–Pro–Thr–Thr, which contains the PI 3-kinase
binding site.
CD28 and CTLA-4 share common ligands, the B7-related
molecules CD80 and CD86; CTLA-4 binds CD80 and
CD86 with much higher avidity than does CD28. A
soluble CTLA-4–immunoglobulin hybrid construct,
CTLA4Ig, showed high avidity binding to CD80 and
CD86 and has remarkable inhibitory effects on lympho-
cyte functions, both in vitro and in vivo. This indicates that
molecules bound by the B7 ligands are involved in stimu-
lating lymphocyte activation. However, because of the
possible involvement in these interactions of both CD28
and CTLA-4, analysis of the individual role of CTLA-4
had to await the availability of specific reagents and/or
procedures. 
Studies of CTLA-4 function using monoclonal antibodies
Addition of anti-CTLA-4 monoclonal antibodies to in vitro
model systems of T-cell activation generally leads to
increased T-cell proliferation, but the mechanism by
which this occurs has been controversial [1,2]. Early studies
interpreted the effects as evidence that CTLA-4 is a cos-
timulatory receptor, analogous to, but weaker than, CD28.
However, the stimulatory effects of anti-CTLA-4 mono-
clonal antibodies have also been attributed to blocking of
CTLA-4–B7 interactions, which have an inherently nega-
tive effect on T-cell activation [5] — by blocking an inter-
action that has inhibitory effects, T-cell activation is
increased. This interpretation was supported by the obser-
vation that intact anti-CTLA-4 antibody had similar effects
to those of Fab fragments of the antibody, even though
Fab fragments were presumably unable to signal. Similar
effects of anti-CTLA-4 antibodies were also seen in an in
vivo model of T-cell expansion [6]. Thus, two seemingly
exclusive models predicted either positive or negative
effects of CTLA-4 engagement during T-cell activation.
A new study has examined the effects of anti-CTLA-4
monoclonal antibodies on anti-tumor immunity [7].
Administration of anti-CTLA-4 antibodies to tumor-
bearing animals led to striking tumor regression and
immunity to rechallenge. These effects were seen even
when animals bearing established tumors were treated
with anti-CTLA-4 antibody. Surprisingly, administration
of anti-CD28 antibodies did not have similar results; thus,
anti-CTLA-4 antibodies specifically stimulated anti-
tumor immunity. As with previous studies of the effects of
anti-CTLA-4 monoclonal antibodies, the immune-stimu-
latory effect of the anti-CTLA-4 monoclonal antibodies
could have resulted from direct stimulation of anti-tumor
antigen-specific T cells, or from blocking negative effects
of CTLA-4 on T-cell activation. Although the antibodies
used for these experiments apparently block the binding
of CTLA4Ig to B7 molecules, it is unclear whether the
negative effects of CTLA-4 require its engagement by B7
molecules. Regardless of the mechanism, this study
clearly establishes the potential benefits of anti-CTLA-4
monoclonal antibodies for stimulating anti-tumor immu-
nity. It will be important to extend these studies to other
tumor systems.
Knockout mice
Our view of CTLA-4 has been transformed by two studies
describing CTLA-4 gene knockout mice [8,9]. In both
cases, heterozygous (+/–) mice appeared healthy, but
CTLA-4 null mutant (–/–) mice showed severe lympho-
proliferative disorders and early lethality (within 3–4
weeks after birth). T-cell blasts (having an
activated/memory cell-surface marker phenotype) accu-
mulated in the peripheral lymphoid organs of CTLA-4-
deficient mice, and serum immunoglobulin levels were
elevated up to about 100-fold for some isotypes [8]. Mice
from both laboratories suffered massive lymphocytic infil-
tration of several internal organs, including the heart and
pancreas. In contrast, mice lacking CD28 had only rela-
tively minor defects in peripheral immune responses.
At this juncture, we have learned that CTLA-4 and CD28
have inherently different properties and functions,
although they have some sequence homology and share
common ligands (Table 1). But many new questions come
to mind. For example, what is the role of CTLA-4 during
development? The early lethality seen in CTLA-4-defi-
cient mice indicates that CTLA-4 is vitally important
early in development of the immune system. Surprisingly,
however, patterns of CTLA-4 expression during develop-
ment are unknown; to our knowledge, there is no informa-
tion available on the cellular expression of CTLA-4
around or before birth. And what is the effect of CTLA-4
on activation of mature T cells? Both the knockout mice
and studies with monoclonal antibodies have suggested
that the role of CTLA-4 is negative, but the early defects
in the CTLA-4-deficient mice make it difficult to ascer-
tain the effects of the absence of this molecule on mature
T cells. Thus, it is unclear whether the negative regula-
tory effects of the CTLA-4 gene have the same cellular
and molecular basis as the inhibitory effects of anti-
CTLA-4 monoclonal antibodies. Also, many experiments
have shown stimulatory effects of anti-CTLA-4 mono-
clonal antibodies. Might CTLA-4 have additional stimula-
tory effects in addition to its negative regulatory role? And
why is there is a lack of lymphocyte control in CTLA-4-
deficient mice? This could be due to a failure in develop-
ment of thymic or peripheral tolerance in these mice. For
example, CTLA-4 might be required for effective nega-
tive selection of autoreactive clones. The lack of periph-
eral control might also indicate increased activation in the
periphery of normally selected T cells. 
The results so far also raise questions about the possible
relationship between CTLA-4 and cell death. Why, in
CTLA-4-deficient mice is there no control of lymphocyte
activation by normal mechanisms, such as the Fas/Fas-
ligand (FasL) cell-death triggering system? Although
peripheral T cells from CTLA-4-deficient mice were sen-
sitive to cell death induced by crosslinking of the Fas
receptor [8], these mice might nevertheless have alter-
ations in the Fas/FasL system. Supporting this possibility
was the detection in the livers of CTLA-4-deficient mice
of aggregates of (most probably activated) mononuclear
cells in the absence of tissue destruction. Liver cells are
very sensitive to Fas-based killing; the infiltrating, pre-
sumably activated, lymphocytes should express the Fas
ligand. Nonetheless, there was no obvious tissue destruc-
tion. Another hint of Fas/FasL alterations was the sponta-
neous proliferation in vitro of lymph-node cells from
CTLA4-deficient mice. These cells should be killed, at
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Table 1
Contrasting properties of T-cell receptors CD28 and CTLA-4
Property CD28 CTLA-4
Binding to CD80 and CD86 Low avidity High avidity
T lymphocyte expression:
Type of expression Constitutive Inducible
Time during T-cell response Continuous Late
Levels on cell surface Moderate  Very low
Primary subcellular localization Cell surface Intracellular
Effect on T-cell proliferation of:
Intact antibodies Strong stimulation Weak stimulation
Crosslinked antibodies Strong stimulation Strong inhibition
Effect of gene deletion Mild immuno- Lethal lympho-
suppression proliferation
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least in part, by Fas–FasL interactions. Possibly CTLA-4
expression is required for Fas/FasL expression on acti-
vated T cells around birth. Alternatively, CTLA-4 might
play another direct or indirect role in regulating death of T
lymphocytes.
Finally, is there a role for CTLA-4 abnormalities in human
disease? Mutations in many important lymphocyte mole-
cules cause similar immunodeficiencies in mice and man.
Now that the severe phenotype of CTLA-4 deficiency in
mice has been determined, it will be important to deter-
mine whether CTLA-4 deficiencies cause a similar pheno-
type in humans. Perhaps CTLA-4 deficiencies will turn
up in newborn or very young children with lymphoprolif-
erative disorders. It is also possible that older people het-
erozygous for deficiencies in CTLA-4 may be more prone
to autoimmune diseases. As the deficiencies in CTLA-4
homozygous null mice are so profound, gene-dosage
effects on CTLA-4 expression may lead to intermediate
phenotypes. Linkage between the ctla-4 locus and human
autoimmune disorders have been observed [10]. This
finding, together with the recent data from CTLA-4-defi-
cient mice, tells us of a possible role of CTLA-4 abnormal-
ities in the pathogenesis of human disease. 
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